Preliminary Programme

Forum by Fondazione Internazionale Menarini


DAY 1 – 13 July 2018 (Friday)



DAY 2 – 14 July 2018 (Saturday)

(0900-0915h) OPENING ADDRESS

Alessandro Casini, MD

Giuseppe Caracciolo, MD, PhD



Chairpersons: Faiez Zannad (France), Bertram Pitt (US), Lijing Yan (China), Carolyn Lam (Singapore), Alexandre Mebazaa (France)

This opening session serves to describe the epidemiology of cardiovascular disease in Asia Pacific, highlight the unique Asian phenotype of disease, and point out gaps in knowledge as well as unmet needs that should urgently be addressed in cardiovascular clinical trials. Large ongoing registries in Asia will be showcased, offering opportunity for collaboration. Questions to be discussed include: Are regional differences related to differences in health care systems and medical practices or due to true ethnic differences? Do Asian patients really need lower doses than Western patients? How may existing registries be upgraded so as to host registry-nested randomized trials?

Suggested/Invited Speakers:

(0915-0945h)  Hyperlipidemia: Genes versus diet

Asian perspective: Tavintharan Subramaniam (Singapore)

Global perspective: Yves Rosenberg (US)


(0945-1015h)  Diabetes: Lean versus obese diabetic

Asian perspective: Dorairaj Prabhakaran (India)

Global perspective: Mikhail Kosiborod (US)


(1015-1045h)  Coronary artery disease: Micro- versus macro-vascular ischemia

Asian perspective: Adrian Low (Singapore)

Global perspective: Athanasios Manolis (Greece)


(1045-1115h)  Heart Failure: Preserved versus reduced ejection fraction

Asian perspective: Jasper Tromp (Singapore)

Global perspective: Adriaan Voors (Netherlands)


(1115-1200h)  Panelist Discussion

Mark Chan (Singapore)

Peter Fenici (US)

Ruth Gimeno (US)

Zanariah Hussein (Malaysia)

Ge Junbo (China)

Mikhail Kosiborod (US)

Mark Kowala (US)

Athanasios Manolis (Greece)

Alexandre Mebazaa (France)

Daisaku Nakatani (Japan)

Dorairaj Prabhakaran (India)

Yves Rosenberg (US)

Afshin Salsali (US)

Tavintharan Subramaniam (Singapore)

Adriaan Voors (Netherlands)

Scott Wasserman (US)

Lijing Yan (China)

Inder Anand (India)

Ryan Andal (Philippines)

Goh Su Yen (Singapore)

Houng Bang Liew (Malaysia)

Charlie Chung-Lieh Hung (Taiwan)

Lee Fong Ling (Singapore)

Ajay Naik (India)

JPS Sawhney (India)

Suk Keun Hong (South Korea)

Jack Tan (Singapore)

Yong Hyun Kim (South Korea)


(1200-1330h) LUNCH



Chairpersons: Barry Greenberg (US), Peter va der Meer (Netherlands), Myeong-Chan Cho (Korea), David Sim (Singapore), Yasuhiko Sakata (Japan)

Recent large heart failure drug trials have changed the landscape of heart failure management and provided valuable insights into trial design. In particular, the potential geographic differences in patient populations worldwide have been highlighted. The applicability of trial findings in the diverse settings across Asia therefore deserves discussion. Heart failure trials such as RELAX-ASIA and SOCRATES demonstrate the current trend to focus on or involve Asia in combined global trial efforts, in both early and late phases of drug development. The insights gained from such efforts will be discussed.

Suggested/Invited Speakers:

(1330-1355h)  COMMANDER-HF

Invited Speaker: Barry Greenberg (US)

Invited Discussant for Asian perspective: Myeong-Chan Cho (Korea)


(1355-1420h)  VICTORIA
Invited Speaker: Adriaan Voors (Netherlands)

Invited Discussant for Asian perspective: David Sim (Singapore)


(1420-1445h)  EMPEROR

Invited Speaker: Faiez Zannad (France)

Invited Discussant for Asian perspective: Ru San Tan (Singapore)


(1445-1510h)  EFFECT-HF

Invited Speaker: Peter van der Meer (Netherlands)

Invited Discussant for Asian perspective: Iain Macdougall (UK)


(1510-1530h)  Panelist Discussion

Josep Comin-Colet (Spain)

Wolfram Döhner (Germany)

Barry Greenberg (US)

Charlie Chung-Lieh Hung (Taiwan)

Zhang Jian (China)

Ge Junbo (China)

David Kaye (Australia)

Koichiro Kinugawa (Japan)

Joerg Koglin (Germany)

Carolyn Lam (Singapore)

Iain Macdougall (UK)

Alexandre Mebazaa (France)

Claudio Mori (Switzerland)

Christopher Nessel (US)

Lothar Roessig (Germany)

Afshin Salsali (US)

Ru San Tan (Singapore)

Faiez Zannad (France)

Ryan Andal (Philippines)

JPS Sawhney (India)

Suk Keun Hong (South Korea)

Lee Fong Ling (Singapore)

Houng Bang Liew (Malaysia)

Ajay Naik (India)

Yong Hyun Kim (South Korea)

Inder Anand (India)

(1530-1600h) COFFEE BREAK



Chairpersons: Martin Huelsmann (UK), Torbjorn Omland (Norway), Toon-Wei Lim (Singapore), Chi Keong Ching (Singapore)

Device-based interventions are well accepted in international guidelines but remain under-used in Asia. Important geographic and/or ethnic differences may contribute to different practices across Asia. The utility of remote monitoring will be discussed, particularly within the context of Asia.

Suggested/Invited Speakers:

(1600-1620h) Biomarkers for risk stratification: Where we are & where we’re heading

Invited Speaker: Torbjorn Omland (Norway)

Invited Discussant for Asian perspective: Calvin Chin (Singapore)

 (1620-1640h) PONTIAC I & II: Biomarker-guided therapy in diabetes?

Invited Speaker: Martin Huelsmann (UK)

Invited Discussant for Asian perspective: Carolyn Lam (Singapore)


(1640-1700h) MANAGE-HF: What’s new in telemedicine?

Invited Speaker: Ken Stein (US)

Invited Discussant for Asian perspective: Raymond Wong (Singapore)


(1700-1720h) REDUCE-LAP: Device cure for HFpEF?

Invited Speaker: David Kaye (Australia)

Invited Discussant for Asian perspective: Toon-Wei Lim (Singapore)


(1720-1740h) VIP-HF: HFpEF-AF vicious twins?

Invited Speaker: Peter van der Meer (Netherlands)

Invited Discussant for Asian perspective: Chi Keong Ching (Singapore)


(1740-1800h) Panelist Discussion

Calvin Chin (Singapore)

David Kaye (Australia)

Frank Kramer (Germany)

Carolyn Lam (Singapore)

Alexandre Mebazaa (France)

Torbjorn Omland (Norway)

Ken Stein (US)

Peter van der Meer (Netherlands)

Raymond Wong (Singapore)

Tijana Krnjeta Janicijevic (Switzerland)

Irma Wang (Switzerland)

Houng Bang Liew (Malaysia)

Ryan Andal (Philippines)

JPS Sawhney (India)

Suk Keun Hong (South Korea)

Lee Fong Ling (Singapore)

Jack Tan (Singapore)

Chi Tze Tan (Singapore)

Andrea Ballagi (Sweden)

Charlie Chung-Lieh Hung (Taiwan)

Ajay Naik (India)

Yong Hyun Kim (South Korea)

Inder Anand (India)



DAY 3 – 15 JULY 2018 (Sunday)


Chairpersons: Wilson Tang (US), Adriaan Voors (Netherlands), Faiez Zannad (France), Carolyn Lam (Singapore), Patrick Tan (Singapore)

The dream of a precision medicine approach in Cardiology is becoming a reality. Wider use of electronic medical records generates big data that are being increasingly used in streamlined prospective clinical trials as well as in registry and observational studies. Results are offered as hypothesis generating or as assessments of effectiveness, occasionally challenging, and hopefully complementing, the results of randomized-controlled clinical trials. This session focuses on ongoing efforts in Asia and worldwide, and aims to discuss the far-reaching potential of this approach.

Suggested/Invited Speakers:

(0900-0915h) Multimarker approaches in precision medicine

Invited Speaker (15 mins): Alexandre Mebazaa (France)


(0915-0930h) PRISM: Precision medicine in Asia

Invited Speaker: Patrick Tan (Singapore)


(0930-0945h) ATTRaCT: The Asian model

Invited Speaker: Frank Eisenhaber (Singapore)


(0945-1000h) BIOSTAT: The European model

Invited Speaker: Adriaan Voors (Netherlands)


(1000-1015h) Operationalizing precision cardiovascular medicine: The US model

Invited Speaker (15 mins): Wilson Tang (US)

(1015-1030h) Regulator’s perspective on precision medicine

Invited Speaker: Kaori Shinagawa (Japan)

(1030-1045h) Editor’s perspective on precision medicine

Invited Speaker: Stuart Spencer (UK)

(1045-1100h) Industry perspective on precision medicine

Invited Speaker (15 mins): Scott Wasserman (US)


(1100-1130h) Wrap-up & discussion

Chaired by course directors Carolyn Lam (Singapore), Faiez Zannad (France), Bertram Pitt (US)


Discussnat: Robert Mentz (US)

(1130-1300h) BRUNCH